MyMD: Funding, Investors & Team (Oct 2026)
MyMD is a pharmaceutical company with a focus on developing two therapeutic platforms to extend healthy lifespan. MYMD-1 is a drug platform based on a small molecule that regulates the immunometabolic system to control pro-inflammatory cytokines and is being developed to treat autoimmune diseases and aging. SUPERA-CBD is a drug platform based on a synthetic derivative of CBD that targets key receptors and is being developed to address the growing CBD market.
MyMD has raised $22.0M across 2 funding rounds on record, the most recent an undisclosed round of $7.0M announced in May 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
MyMD Company Profile and Key Stats
Latest funding round on record: May 2024.
MyMD Funding Rounds
MyMD raised $15.0M in an undisclosed round announced in Feb 2023.
1.3 years later, an undisclosed round of $7.0M was announced in May 2024.
MyMD Founders and Leadership Team
No contact details are on record for this team yet.
MyMD Funding Compared to Other Biotechnology Startups
MyMD's latest round of $7.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like MyMD in Biotechnology and Baltimore
Companies Similar to MyMD
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
MyMD Funding FAQs
What does MyMD do?
MyMD is a pharmaceutical company with a focus on developing two therapeutic platforms to extend healthy lifespan. MYMD-1 is a drug platform based on a small molecule that regulates the immunometabolic system to control pro-inflammatory cytokines and is being developed to treat autoimmune diseases and aging. SUPERA-CBD is a drug platform based on a synthetic derivative of CBD that targets key receptors and is being developed to address the growing CBD market.
How much funding has MyMD raised?
MyMD has raised $22.0M across 2 rounds on record. The most recent is an undisclosed round of $7.0M announced in May 2024.
When did MyMD last raise funding?
MyMD's most recent funding round on record is an undisclosed round of $7.0M, announced in May 2024.
Who founded MyMD?
FundedIQ lists Jeremy Smith (Founder) at MyMD.
Who is the CEO of MyMD?
James A Mcnulty is listed as CEO at MyMD.
Where is MyMD headquartered?
MyMD is based in Baltimore, Maryland, United States.
How many employees does MyMD have?
MyMD is in the 1-10 employee band.
How does MyMD's funding compare to other Biotechnology startups?
MyMD's latest round of $7.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's MyMD Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for MyMD is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.